The 2022 hormone therapy position statement of The North American Menopause Society

医学 更年期 激素疗法 立场声明 激素替代疗法(女性对男性) 重症监护医学 物理疗法 内科学 家庭医学 睾酮(贴片) 乳腺癌 癌症
作者
Stephanie S. Faubion,Carolyn J. Crandall,Lori A. Davis,Samar R. El Khoudary,Howard Neil Hodis,Roger A. Lobo,Pauline M. Maki,JoAnn Elisabeth Manson,JoAnn Elisabeth Manson,Nanette F. Santoro,Jan Leslie Shifren,CHRISANDRA L. SHUFELT,Rebecca C. Thurston,Wendy Wolfman
出处
期刊:Menopause [Lippincott Williams & Wilkins]
卷期号:29 (7): 767-794 被引量:1241
标识
DOI:10.1097/gme.0000000000002028
摘要

ABSTRACT: "The 2022 Hormone Therapy Position Statement of The North American Menopause Society" (NAMS) updates "The 2017 Hormone Therapy Position Statement of The North American Menopause Society" and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women's health and menopause was recruited by NAMS to review the 2017 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence. The Advisory Panel's recommendations were reviewed and approved by the NAMS Board of Trustees.Hormone therapy remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture. The risks of hormone therapy differ depending on type, dose, duration of use, route of administration, timing of initiation, and whether a progestogen is used. Treatment should be individualized using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation of the benefits and risks of continuing therapy.For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome VMS and prevention of bone loss. For women who initiate hormone therapy more than 10 years from menopause onset or who are aged older than 60 years, the benefit-risk ratio appears less favorable because of the greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia. Longer durations of therapy should be for documented indications such as persistent VMS, with shared decision-making and periodic reevaluation. For bothersome genitourinary syndrome of menopause symptoms not relieved with over-the-counter therapies in women without indications for use of systemic hormone therapy, low-dose vaginal estrogen therapy or other therapies (eg, vaginal dehydroepiandrosterone or oral ospemifene) are recommended.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
无花果的应助被w1277766424采纳,获得10
刚刚
刚刚
叽叽发布了新的文献求助10
刚刚
圆圆发布了新的文献求助10
1秒前
万能图书馆的应助被Q52采纳,获得10
2秒前
2秒前
TCA发布了新的文献求助10
3秒前
huii的应助被visz采纳,获得10
3秒前
www完成签到,获得积分10
3秒前
三斤发布了新的文献求助10
4秒前
4秒前
科研通AI65的应助被杨茜然采纳,获得10
4秒前
4秒前
云起一生完成签到,获得积分10
4秒前
包包完成签到 ,获得积分10
4秒前
汉堡包的应助被果果采纳,获得10
4秒前
4秒前
科研通AI6.4的应助被Panda采纳,获得10
5秒前
脑洞疼的应助被云儿采纳,获得10
6秒前
小小完成签到,获得积分10
6秒前
水牛发布了新的文献求助10
7秒前
我我发布了新的文献求助10
7秒前
彩色的荔枝完成签到,获得积分10
7秒前
8秒前
万能图书馆的应助被qq采纳,获得10
8秒前
小了白了兔完成签到,获得积分10
8秒前
itsdeva完成签到,获得积分10
9秒前
张毛毛完成签到,获得积分10
9秒前
xiaolei完成签到 ,获得积分0
9秒前
shenkekeshen的应助被Rk采纳,获得10
9秒前
脑洞疼的应助被积极的中蓝采纳,获得10
10秒前
10秒前
10秒前
Eric的应助被彩色的荔枝采纳,获得10
10秒前
liyuxing发布了新的文献求助10
10秒前
寒渡川发布了新的文献求助10
11秒前
没啥鱼丸完成签到 ,获得积分10
11秒前
12秒前
仁爱的觅风完成签到 ,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193690
求助须知:如何正确求助?哪些是违规求助? 9579864
关于积分的说明 21868057
捐赠科研通 7793415
什么是DOI,文献DOI怎么找? 3437414
关于科研通互助平台的介绍 2560832
邀请新用户注册赠送积分活动 2484206